secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001493152-23-018481
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell closes $4M strategic investment by Prevail Partners at $8.63/share
---------------------------------------------------------------------------

- Issued 463,408 common shares to Prevail Partners for aggregate gross proceeds of $4 million.
- Price per share was US$8.63; TSX approved the transaction on May 18, 2023.
- Proceeds to fund CRO clinical services and technologies for upcoming pivotal study in advanced metastatic breast cancer.
- Shares subject to four-month-and-one-day hold period under Canadian securities laws.
- Prevail Partners' affiliate, Prevail InfoWorks, will provide clinical services and real-time data analytics platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223018481/0001493152-23-018481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223018481/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-018481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer